AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26079418 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative diagnostic scenario for MCI classification
Number of subjects: 153
Study 26079418 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroimaging features comparison
Number of subjects: 153
Study 26079776 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term Intensive Insulin Therapy (IIT) for 4 weeks, consisting of basal detemir and premeal insulin aspart.
Number of subjects: 62
Study 26081121 — intervention group
Group type: EXPERIMENTAL
Intervention: First-degree relatives (FDR)
Number of subjects: 100
Study 26081121 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysglycaemic subjects
Number of subjects: 100
Study 26081121 — intervention group
Group type: COMPARATOR
Intervention: Normoglycaemic subjects
Number of subjects: 100
Study 26081793 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 127
Study 26081793 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 127
Study 26081793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 26082320 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline Chlamydia trachomatis infection
Number of subjects: 2004
Study 26082320 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥2 sexual partners during follow-up
Number of subjects: 2004
Study 26082320 — intervention group
Group type: EXPERIMENTAL
Intervention: New sexual partner during follow-up
Number of subjects: 2004
Study 26082320 — intervention group
Group type: EXPERIMENTAL
Intervention: Age <20 years
Number of subjects: 2004
Study 26082320 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment from a further education college rather than a university
Number of subjects: 2004
Study 26082320 — intervention group
Group type: EXPERIMENTAL
Intervention: History of vaginal discharge at baseline
Number of subjects: 2004
Study 26082320 — intervention group
Group type: EXPERIMENTAL
Intervention: History of pelvic pain at baseline
Number of subjects: 2004
Study 26082320 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial vaginosis and Mycoplasma genitalium infection
Number of subjects: 2004
Study 26082332 — intervention group
Group type: EXPERIMENTAL
Intervention: Onalespib (AT13387) at RP2D of 160 mg/m(2)/dose administered on days 1, 2, 8, 9, 15, and 16 of 28 day cycles (QDx2/week)
Number of subjects: 31
Study 26082332 — intervention group
Group type: EXPERIMENTAL
Intervention: Onalespib (AT13387)
Number of subjects: 31
Study 26082464 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingestion of virulent S. Paratyphi A bacteria (NVGH308 strain) with a bicarbonate buffer solution to establish the infectious dose.
Number of subjects: 20
Study 26082815 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral levosimendan (0.125 to 2.0 mg daily for 18-day intervals)
Number of subjects: 16
Study 26082815 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral levosimendan (≥0.5 mg)
Number of subjects: 16
Study 26082815 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral levosimendan (2.0 mg)
Number of subjects: 16
Study 26082815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 26082920 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel brain and vestibular rehabilitation (VR) treatment for PTSD
Number of subjects: 26
Study 26083135 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive model-based dose-ranging trial
Number of subjects: 0
Study 26083256 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib 1500 mg daily in monthly cycles
Number of subjects: 22
Study 26083430 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic plasma exchanges (TPE) and rituximab, supplemented with intravenous immunoglobulin (IVIG) in later cases
Number of subjects: 11
Study 26083430 — intervention group
Group type: COMPARATOR
Intervention: Conventional glucocorticoid therapy
Number of subjects: 11
Study 26083430 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic plasma exchanges (TPE)
Number of subjects: 11
Study 26084369 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visits by Community Health Workers (VHTs) combined with mobile phone consultations with professional health workers.
Number of subjects: 36
Study 26084369 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone consultations between VHTs and professional health workers.
Number of subjects: 36
Study 26084369 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visits made by VHTs for maternal and newborn care.
Number of subjects: 36
Study 26084369 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of recommended maternal and newborn care practices by VHTs.
Number of subjects: 36
Study 26084369 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaboration between VHTs and professional health workers.
Number of subjects: 36
Study 26084397 — intervention group
Group type: EXPERIMENTAL
Intervention: ARAT-2 (sum score 0-6, cut-off at 2 points)
Number of subjects: 112
Study 26084397 — intervention group
Group type: EXPERIMENTAL
Intervention: ARAT-2 at 3 days post-stroke
Number of subjects: 112
Study 26084515 — intervention group
Group type: EXPERIMENTAL
Intervention: FLU-v
Number of subjects: 0
Study 26084515 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26084896 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal intubation (ETI) in the ICU
Number of subjects: 885
Study 26084896 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors predictive of severe CVC
Number of subjects: 885
Study 26084934 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress Doppler echocardiography (SDE) during low-dose exercise
Number of subjects: 76
Study 26084934 — intervention group
Group type: COMPARATOR
Intervention: Echocardiography at rest
Number of subjects: 76
Study 26084989 — intervention group
Group type: EXPERIMENTAL
Intervention: Alisertib 30 mg BID
Number of subjects: 36
Study 26084989 — intervention group
Group type: EXPERIMENTAL
Intervention: Alisertib 40 mg BID
Number of subjects: 36
Study 26084990 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral MK-2206 at a dose of 200 mg administered on days 1, 8, 15, and 22 of a 28-day cycle until progression.
Number of subjects: 21
Study 26085490 — intervention group
Group type: EXPERIMENTAL
Intervention: Candidate set A (7 joints, 2 tendons)
Number of subjects: 439
Study 26085490 — intervention group
Group type: EXPERIMENTAL
Intervention: Candidate set B (9 joints, 2 tendons)
Number of subjects: 439
Study 26085490 — intervention group
Group type: EXPERIMENTAL
Intervention: Candidate sets A and B
Number of subjects: 439
Study 26085490 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced GSUS and PDUS scores
Number of subjects: 439
Study 26086290 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 26086330 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher 24-hour RQ
Number of subjects: 107
Study 26086330 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher 24-hour EE
Number of subjects: 107
Study 26086330 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous physical activity
Number of subjects: 107
Study 26086330 — intervention group
Group type: EXPERIMENTAL
Intervention: Awake and fed thermogenesis
Number of subjects: 107
Study 26086330 — intervention group
Group type: EXPERIMENTAL
Intervention: FFM
Number of subjects: 107
Study 26087201 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom endotoxin exposure
Number of subjects: 248
Study 26087201 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom air endotoxin levels
Number of subjects: 248
Study 26087201 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom settled dust endotoxin levels
Number of subjects: 248
Study 26087201 — intervention group
Group type: EXPERIMENTAL
Intervention: Airborne endotoxin levels in classrooms
Number of subjects: 248
Study 26087348 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical catastrophizing (PCS score ≥30)
Number of subjects: 105
Study 26087348 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher PCS scores
Number of subjects: 105
Study 26087348 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher BMI
Number of subjects: 105
Study 26087668 — intervention group
Group type: EXPERIMENTAL
Intervention: LVAD decision-making process
Number of subjects: 45
Study 26087668 — intervention group
Group type: EXPERIMENTAL
Intervention: Informational needs regarding LVAD
Number of subjects: 45
Study 26087668 — intervention group
Group type: EXPERIMENTAL
Intervention: Need for peer support
Number of subjects: 45
Study 26087668 — intervention group
Group type: EXPERIMENTAL
Intervention: Decisional Regret Scale
Number of subjects: 45
Study 26087668 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarification of transplant status
Number of subjects: 45
Study 26087985 — intervention group
Group type: EXPERIMENTAL
Intervention: Good School Toolkit (intervention)
Number of subjects: 4138
Study 26087985 — intervention group
Group type: COMPARATOR
Intervention: Waitlisted control group
Number of subjects: 4138
Study 26088117 — intervention group
Group type: EXPERIMENTAL
Intervention: fMRI-based neurofeedback (fMRI-NF)
Number of subjects: 0
Study 26088117 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 26088649 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative goal-directed therapy (PGDT) with standardized baseline crystalloid administration of 3 ml/kg/hour and additional boluses based on PGDT.
Number of subjects: 330
Study 26088649 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative goal-directed therapy (PGDT) implementation.
Number of subjects: 330
Study 26088768 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin
Number of subjects: 0
Study 26088768 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine
Number of subjects: 0
Study 26088768 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumefantrine
Number of subjects: 0
Study 26088768 — intervention group
Group type: EXPERIMENTAL
Intervention: Monodesethylamodiaquine
Number of subjects: 0
Study 26088768 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine
Number of subjects: 0
Study 26088768 — intervention group
Group type: COMPARATOR
Intervention: Quinine
Number of subjects: 0
Study 26088768 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin, Mefloquine, Chloroquine
Number of subjects: 0
Study 26088932 — intervention group
Group type: EXPERIMENTAL
Intervention: National Institutes of Health Eye Score
Number of subjects: 210
Study 26088932 — intervention group
Group type: EXPERIMENTAL
Intervention: Schirmer's tear test
Number of subjects: 210
Study 26088932 — intervention group
Group type: EXPERIMENTAL
Intervention: Lee ocular subscale
Number of subjects: 210
Study 26088932 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxford grand total staining
Number of subjects: 210
Study 26088932 — intervention group
Group type: EXPERIMENTAL
Intervention: Meibomian score
Number of subjects: 210
Study 26088933 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib 15 mg orally twice daily plus lenalidomide 5 mg orally once daily on days 1-21
Number of subjects: 31
Study 26088933 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib and lenalidomide combination therapy
Number of subjects: 31
Study 26089177 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombotic therapies
Number of subjects: 37815
Study 26089212 — intervention group
Group type: EXPERIMENTAL
Intervention: AcrySof Toric IOL
Number of subjects: 75
Study 26089222 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg of oral solithromycin
Number of subjects: 59
Study 26089222 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg of oral solithromycin
Number of subjects: 59
Study 26089222 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses of solithromycin (1200 mg and 1000 mg)
Number of subjects: 59
Study 26089253 — intervention group
Group type: EXPERIMENTAL
Intervention: Men's Prostate Awareness Church Training (M-PACT) intervention, consisting of 4 bimonthly men's health workshops.
Number of subjects: 0
Study 26089253 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-sex workshops (including women)
Number of subjects: 0
Study 26089253 — intervention group
Group type: COMPARATOR
Intervention: Men-only workshops
Number of subjects: 0
Study 26089253 — intervention group
Group type: EXPERIMENTAL
Intervention: Encouragement for men to invite women to workshops
Number of subjects: 0
Study 26089397 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemoimmunotherapy with doxorubicin- and rituximab-based regimens; 93 patients received consolidation radiotherapy.
Number of subjects: 103
Study 26089686 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib (5 mg twice daily)
Number of subjects: 204
Study 26089686 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib (400 mg twice daily)
Number of subjects: 204
Study 26089686 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib
Number of subjects: 204
Study 26089951 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine (CHM)
Number of subjects: 0
Study 26089951 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26091915 — intervention group
Group type: EXPERIMENTAL
Intervention: Ridaforolimus 20 mg daily days 1-5 with vorinostat 100 mg BID days 1-3 weekly (MTD)
Number of subjects: 15
Study 26091915 — intervention group
Group type: EXPERIMENTAL
Intervention: Ridaforolimus 20 mg daily days 1-5 with vorinostat 100 mg daily days 1-3 weekly (recommended phase II dose)
Number of subjects: 15
Study 26092045 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% dimethicone
Number of subjects: 58
Study 26092537 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod therapy
Number of subjects: 27
Study 26093174 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoriasis
Number of subjects: 122
Study 26093174 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopic Dermatitis (AD)
Number of subjects: 122
Study 26093174 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 122
Study 26093811 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 120 mg
Number of subjects: 5677
Study 26093811 — intervention group
Group type: COMPARATOR
Intervention: Zoledronic acid 4 mg
Number of subjects: 5677
Study 26093862 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulants
Number of subjects: 800000
Study 26093862 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 800000
Study 26093862 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 800000
Study 26093862 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered outcomes
Number of subjects: 800000
Study 26093865 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary prevention medications (aspirin, adenosine diphosphate receptor inhibitors, β-blockers, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, statins)
Number of subjects: 7955
Study 26093865 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with nonpersistence
Number of subjects: 7955
Study 26093865 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with higher persistence
Number of subjects: 7955
Study 26093876 — intervention group
Group type: EXPERIMENTAL
Intervention: Holter monitoring during and after marathon race
Number of subjects: 20
Study 26093876 — intervention group
Group type: EXPERIMENTAL
Intervention: Holter monitoring during marathon race
Number of subjects: 20
Study 26093876 — intervention group
Group type: EXPERIMENTAL
Intervention: Postrace assessment of cardiac troponin and IL-6
Number of subjects: 20
Study 26093923 — intervention group
Group type: EXPERIMENTAL
Intervention: Native T1 in remote myocardium (2 days post-STEMI)
Number of subjects: 300
Study 26093923 — intervention group
Group type: EXPERIMENTAL
Intervention: Incomplete ST-segment resolution
Number of subjects: 300
Study 26093923 — intervention group
Group type: EXPERIMENTAL
Intervention: Log of admission C-reactive protein concentration
Number of subjects: 300
Study 26093923 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak monocyte count
Number of subjects: 300
Study 26093923 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote T1 at baseline
Number of subjects: 300
Study 26093923 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in LV end-diastolic volume from baseline to 6 months
Number of subjects: 300
Study 26093923 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote zone native T1
Number of subjects: 300
Study 26093928 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple Rule Out (TRO)
Number of subjects: 12834
Study 26093928 — intervention group
Group type: COMPARATOR
Intervention: Coronary CT Angiography (CTA)
Number of subjects: 12834
Study 26093953 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipiodol localization technique
Number of subjects: 250
Study 26093953 — intervention group
Group type: COMPARATOR
Intervention: Hook-wire localization technique
Number of subjects: 250
Study 26094162 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistent use of DMPA
Number of subjects: 682
Study 26094162 — intervention group
Group type: COMPARATOR
Intervention: Pregnant women not using hormonal contraception
Number of subjects: 682
Study 26094162 — intervention group
Group type: COMPARATOR
Intervention: Women neither pregnant nor using hormonal contraception
Number of subjects: 682
Study 26094162 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistent use of DMPA with HSV2-seropositive partners
Number of subjects: 682
Study 26094162 — intervention group
Group type: COMPARATOR
Intervention: Women neither pregnant nor using hormonal contraception with HSV2-seropositive partners
Number of subjects: 682
Study 26094614 — intervention group
Group type: EXPERIMENTAL
Intervention: L-asparaginase encapsulated in erythrocytes (GRASPA®) at 100 IU/kg
Number of subjects: 30
Study 26094614 — intervention group
Group type: EXPERIMENTAL
Intervention: L-asparaginase encapsulated in erythrocytes (GRASPA®) at 150 IU/kg
Number of subjects: 30
Study 26094614 — intervention group
Group type: EXPERIMENTAL
Intervention: L-asparaginase encapsulated in erythrocytes (GRASPA®) at 50 IU/kg
Number of subjects: 30
Study 26094614 — intervention group
Group type: EXPERIMENTAL
Intervention: L-asparaginase encapsulated in erythrocytes (GRASPA®)
Number of subjects: 30
Study 26094738 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon-alpha plus ribavirin (PegIFN/RBV) therapy
Number of subjects: 105
Study 26094738 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-responders with high MICA level (>100 pg/mL)
Number of subjects: 105
Study 26094738 — intervention group
Group type: COMPARATOR
Intervention: Non-responders
Number of subjects: 105
Study 26094738 — intervention group
Group type: EXPERIMENTAL
Intervention: High baseline MICA level
Number of subjects: 105
Study 26094738 — intervention group
Group type: EXPERIMENTAL
Intervention: Low platelet count (<100,000/mm3)
Number of subjects: 105
Study 26095067 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes (DM) in individuals with latent tuberculosis (LTB)
Number of subjects: 0
Study 26095067 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes (DM) in individuals with pulmonary tuberculosis (PTB)
Number of subjects: 0
Study 26095067 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes (DM) in individuals with pulmonary tuberculosis (PTB), latent tuberculosis (LTB), and non-TB-infected individuals (NTB)
Number of subjects: 0
Study 26095521 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematopoietic cell transplant (HCT) for severe MPS IH
Number of subjects: 89
Study 26095521 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy for attenuated MPS I
Number of subjects: 89
Study 26095521 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 89
Study 26095669 — intervention group
Group type: EXPERIMENTAL
Intervention: Alefacept (0.25 mg/kg/dose on days -40 and -9; 0.5 mg/kg/dose on days -33, -26, -19, and -12)
Number of subjects: 3
Study 26095746 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarucizumab (5 g intravenous)
Number of subjects: 90
Study 26095785 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent radiotherapy (35 Gy in ten fractions, over 2 weeks) and granulocyte-macrophage colony-stimulating factor (125 μg/m(2) subcutaneously injected daily for 2 weeks, starting during the second week of radiotherapy)
Number of subjects: 41
Study 26095785 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent radiotherapy and granulocyte-macrophage colony-stimulating factor
Number of subjects: 41
Study 26096064 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen time (duration of viewing TV, using computer, playing video games)
Number of subjects: 358
Study 26096743 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 26097680 — intervention group
Group type: EXPERIMENTAL
Intervention: 300IR 5-grass pollen tablet (2 months prior to pollen season)
Number of subjects: 633
Study 26097680 — intervention group
Group type: EXPERIMENTAL
Intervention: 300IR 5-grass pollen tablet (4 months prior to pollen season)
Number of subjects: 633
Study 26097680 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary efficacy measures (both post-treatment years)
Number of subjects: 633
Study 26097680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 633
Study 26097986 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD3043 1-minute bolus IV infusion (1, 1.5, 2, 4, and 6 mg/kg)
Number of subjects: 72
Study 26097986 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD3043 1-minute bolus followed by 30-minute infusion (0.8 + 10, 1 + 15, 3 + 30, and 4 + 40 mg/kg)
Number of subjects: 72
Study 26098143 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous interferon β-1a (Rebif®, Merck Serono SA) 44 or 22 μg three times weekly
Number of subjects: 912
Study 26098143 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 912
Study 26098215 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresolimumab (1 mg/kg, 2 doses)
Number of subjects: 15
Study 26098215 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresolimumab (5 mg/kg, 1 dose)
Number of subjects: 15
Study 26098589 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac magnetic resonance imaging (CMR) including cine and late gadolinium enhancement (LGE) imaging
Number of subjects: 177
Study 26098589 — intervention group
Group type: EXPERIMENTAL
Intervention: Late gadolinium enhancement (LGE) sequences
Number of subjects: 177
Study 26098589 — intervention group
Group type: COMPARATOR
Intervention: Transthoracic echocardiography (TTE)
Number of subjects: 177